{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:24:30Z","timestamp":1790634270538,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,12,18]],"date-time":"2007-12-18T00:00:00Z","timestamp":1197936000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm World Sci"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s11096-007-9181-4","type":"journal-article","created":{"date-parts":[[2007,12,17]],"date-time":"2007-12-17T08:31:24Z","timestamp":1197880284000},"page":"287-292","source":"Crossref","is-referenced-by-count":25,"title":["Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres"],"prefix":"10.1007","volume":"30","author":[{"given":"Virginie","family":"Nerich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Faradji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Demesmay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Anne","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elisabeth","family":"Briquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pouzol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Woronoff-Lemsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,12,18]]},"reference":[{"issue":"1","key":"9181_CR1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1055\/s-2007-994002","volume":"19","author":"BG. Macik","year":"1993","unstructured":"Macik BG. Treatment of factor VIII inhibitors: products and strategies. Semin Thromb Haemost 1993;19(1):13\u201324","journal-title":"Semin Thromb Haemost"},{"issue":"1","key":"9181_CR2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2516.2000.00045.x","volume":"6","author":"DM. DiMichele","year":"2000","unstructured":"DiMichele DM. Inhibitors in haemophilia: a primer. Haemophilia 2000; 6(1):38\u201340","journal-title":"Haemophilia"},{"key":"9181_CR3","doi-asserted-by":"crossref","unstructured":"Sultan Y. The French Hemophilia Study Group. Prevalence of inhibitors in a population of 3,435 hemophilia patients in France. Thromb Haemost 1992;67:600\u20132","DOI":"10.1055\/s-0038-1648507"},{"issue":"1","key":"9181_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2516.2000.00358.x","volume":"6","author":"P Molho","year":"2000","unstructured":"Molho P, Rolland N, Lebrun T, Dirat G, Courpied JP, Croughs T, et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. Haemophilia 2000;6(1):23\u201332","journal-title":"Haemophilia"},{"key":"9181_CR5","first-page":"323","volume":"18","author":"JG Jasso-mosqueda","year":"2000","unstructured":"Jasso-mosqueda JG, Omn\u00e8s LF, Gomez E, et al. Description of the management of patients suffering from type A haemophilia [Description de la prise en charge de l\u2019h\u00e9mophilie s\u00e9v\u00e8re de type A par le programme de m\u00e9dicalisation des Syst\u00e8mes d\u2019information : int\u00e9r\u00eats et limites]. J Econ Med 2000;18:323\u201330","journal-title":"J Econ Med"},{"key":"9181_CR6","first-page":"157","volume":"19","author":"MJ D\u2019Alche-Gautier","year":"2001","unstructured":"D\u2019Alche-Gautier MJ, Gautier P, Stieltjes N, et al. Economic study of clotting factor therapy in haemophilia [Co\u00fbt du traitement substitutif des h\u00e9mophiles hospitalis\u00e9s]. J Econ Med 2001;19:157\u201366","journal-title":"J Econ Med"},{"issue":"1","key":"9181_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2516.2002.00580.x","volume":"8","author":"W Schramm","year":"2002","unstructured":"Schramm W, Royal S, Kroner B, Berntorp E, Giangrande P, Ludlam C, et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002;8(1):33\u201343","journal-title":"Haemophilia"},{"key":"9181_CR8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2516.2004.00950.x","volume":"10","author":"G Auerswald","year":"2004","unstructured":"Auerswald G, Von Depka Prondzinski M, Ehlken B, Kreuz W, Kurnik K, Lenk H, et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004;10:499\u2013508","journal-title":"Haemophilia"},{"issue":"4","key":"9181_CR9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2516.1999.00321.x","volume":"5","author":"H Chang","year":"1999","unstructured":"Chang H, Sher GG, Blanchette VS, Teitel JM. The impact on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia 1999;5(4):247\u201352","journal-title":"Haemophilia"},{"issue":"4","key":"9181_CR10","first-page":"41","volume":"31","author":"GE Rivard","year":"1994","unstructured":"Rivard GE, Vick S. Factor VIII inhibitor treatment. Economics of inhibitor treatment in Canada. Semin Hematol 1994;31(4):41\u20133","journal-title":"Semin Hematol"},{"issue":"1","key":"9181_CR11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2516.2003.00849.x","volume":"10","author":"RL Bohn","year":"2004","unstructured":"Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 2004;10(1):63\u20138","journal-title":"Haemophilia"},{"issue":"5","key":"9181_CR12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1046\/j.1365-2516.2002.00671.x","volume":"8","author":"P Gautier","year":"2002","unstructured":"Gautier P, D\u2019Alche-Gautier MJ, Coatmelec B, Marques-Verdier A, Bertrand MA, Dieval J, et al. Cost related to replacement therapy during hospitalization in haemophiliacs with or without inhibitors: experience of six French haemophilia centres. Haemophilia 2002;8(5):674\u20139","journal-title":"Haemophilia"},{"issue":"6","key":"9181_CR13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2516.1999.00368.x","volume":"5","author":"J. Goudemand","year":"1999","unstructured":"Goudemand J. Hemophilia. Treatment of patients with inhibitors: cost issues. Haemophilia 1999;5(6):397\u2013401","journal-title":"Haemophilia"},{"key":"9181_CR14","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","volume":"339","author":"S Ehrenforth","year":"1992","unstructured":"Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, G\u00fcng\u00f6r T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594\u20138","journal-title":"Lancet"},{"key":"9181_CR15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1046\/j.1365-2516.2001.00457.x","volume":"7","author":"T Calvez","year":"2001","unstructured":"Calvez T, Biou M, Costagliola, Jullien AM, Laurian Y, Rossi F, et al. The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system. Haemophilia 2001;7:82\u20138","journal-title":"Haemophilia"},{"key":"9181_CR16","first-page":"19","volume":"150","author":"FM. Gill","year":"1984","unstructured":"Gill FM. The natural history of factor VIII inhibitors in patients with haemophilia A. Prog Clin Biol Res 1984;150:19\u201329","journal-title":"Prog Clin Biol Res"},{"key":"9181_CR17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0037-1963(01)90144-1","volume":"38","author":"A. Shapiro","year":"2001","unstructured":"Shapiro A. Inhibitor treatment: state of the art. Semin Hematol 2001;38:26\u201334","journal-title":"Semin Hematol"}],"container-title":["Pharmacy World & Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-007-9181-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-007-9181-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-007-9181-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:51:32Z","timestamp":1559368292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-007-9181-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,18]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["9181"],"URL":"https:\/\/doi.org\/10.1007\/s11096-007-9181-4","relation":{},"ISSN":["0928-1231","1573-739X"],"issn-type":[{"value":"0928-1231","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,18]]}}}